問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2015-01-01 - 2016-11-30

Phase I

Completed
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies

  • Condition/Disease

    Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors

  • Test Drug

    ADI-PEG 20

Participate Sites
1Sites

Terminated1Sites

2019-01-01 - 2025-12-31

Phase I

Completed
Phase 1-2 Study of ADI PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular carcinoma

  • Test Drug

    ADI-PEG20

Participate Sites
13Sites

Terminated12Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-04-08 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-05-31 - 2027-12-31

Phase II/III

Active
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

  • Condition/Disease

    Refractory Schizophrenia

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2016-12-01 - 2021-03-22

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2022-09-01 - 2024-12-31

Phase I/II

Completed
A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee

  • Condition/Disease

    Osteoarthritis, Knee

  • Test Drug

    2ccPA

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

  • Condition/Disease

    Relapsed or Resistant Acute Leukaemias

  • Test Drug

    LBS-007

Participate Sites
3Sites

Recruiting3Sites

2024-06-30 - 2029-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2016-06-13 - 2020-12-31

Phase II

Completed
STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial

  • Condition/Disease

    Intracerebral haemorrhage (ICH)

  • Test Drug

    Tranexamic acid

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

周德陽
China Medical University Hospital

Division of Orthopedics

2012-05-01 - 2018-12-03

IIT

Phase III

Completed
Extending the time for Thrombolysis in Emergency Neurological Deficits

  • Condition/Disease

    Acute Ischaemic Stroke

  • Test Drug

    Tissue Plasminogen Activator (tPA)

Participate Sites
9Sites

Suspended8Sites

Study ended1Sites

蔡崇豪
China Medical University Hospital

Division of Neurology

1 92 93 94 95 96 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB